Chinese Methylation Technology Revolutionizes Cervical Cancer Screening: A New Paradigm from Laboratory to Global Clinical Practice
In recent years, as domestic methylation technology has become increasingly mature and widely adopted in China, Chinese methylation technology is expected to continue shining on the international stage.
Let's ask DeepSeek about its understanding of international conferences!
(Taking the EUROGIN Congress as an example)
The EUROGIN Congress's Unique Focus:
Centered on HPV and cervical cancer, covering the entire chain from basic research to clinical practice and public health.
Emphasizes technology innovation and resource equity, promoting screening technology accessibility and vaccine availability.
Focuses on global collaboration, particularly addressing the needs of low- and middle-income countries, supporting the global goal of eliminating cervical cancer.
So how do we participate in such international conferences?
The ESGO meeting (European Society of Gynaecological Oncology) is Europe's leading gynecologic cancer research organization, dedicated to improving the health and well-being of gynecologic cancer patients through prevention, excellence in care, high-quality research, and education.
For such international conferences, especially to present as an oral report, submitters need to complete their abstracts. Submission and conference opening dates should be identified early on the official website. International conferences are a larger global stage, and in the coming years, more Chinese methylation research is expected to appear at international conferences like ESGO.
CISPOLY's methylation technology has participated in numerous well-known international conferences in recent years, including EUROGIN, ESGO, International Conference on Gynecology and Obstetrics, and others.
At the 2024 25th European Society of Gynaecological Oncology (ESGO) Congress, CISPOLY and domestic physician collaborators presented the CISENDO® endometrial cancer (CDO1 and CELF4) methylation non-invasive screening plan as an oral presentation for the first time at ESGO, receiving high praise from Nadeem R. Abu-Rustum, Chair of the endometrial cancer session from Memorial Sloan Kettering Cancer Center, USA.
About the CISENDO® Endometrial Cancer Methylation Detection Kit
The National Medical Products Administration (NMPA) approved the product registration application for the "Human CDO1 and CELF4 Gene Methylation Detection Kit (PCR-Fluorescent Probe Method)" (Trade name: CISENDO® Endometrial Cancer Methylation Detection Kit) (Registration No.: 20243402610) — the first approved non-invasive endometrial cancer detection product. Using cervical-collected specimens combined with CDO1 and CELF4 gene methylation detection technology, it effectively reduces the risks and operational difficulty of traditional intrauterine sampling and demonstrates excellent detection performance, with a sensitivity of 94.51% and specificity of 94.16%. It avoids the risks associated with intrauterine sampling and is suitable for widespread adoption in outpatient and primary healthcare settings. Additionally, this technology enables non-invasive methylation assessment prior to hysteroscopy, significantly reducing the risk of physical injury to patients and providing a safer, more convenient solution for early endometrial cancer screening.
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.